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A b s t r a c t  
The aim of the present study was to develop acyclovir (ACV) ocular drug delivery systems of bovine 
serum albumin (BSA) nanoparticles as well as to assess their in vivo transcorneal permeability. The 
ACV-loaded nanoparticles with 4 % and 8 % drug loading were prepared by desolvation method. 
Morphology of the nanoparticles under scanning electron microscopy was spherical in shape and 
uniform in size. The mean sizes and entrapment efficiencies of ACV-loaded BSA nanoparticles were 
in the range of 125 - 132 nm and 15 - 25 %, respectively. Increasing the amount of ACV added into 
the formulation led to significant reduction of entrapment efficiency of nanoparticles. The results from 
in vivo transcorneal permeation studies revealed that ACV-loaded BSA nanoparticles could readily 
permeate through the rabbits’ cornea and bring about maximum ACV concentrations within 30 min 
and prolonged till 120 min. 
Keywords: Nanoparticles, Acyclovir, Bovine serum albumin, Transcorneal permeability, Ocular drug 
delivery. 
 
 
 
 
 
Introduction 
The major problems encountered with the ophthalmic drug 
delivery are rapid and extensive precorneal loss caused by 
drainage and high tear fluid turnover [1]. Only 1 - 2 % of the 
instilled dose penetrates the cornea and reaches intraocular 
tissues, while a major fraction of the instilled dose is often 
absorbed systemically via the conjunctiva and nasolacrimal duct. 
Strategies to optimize the residence time of the preparations in 
the precorneal area by the use of viscous solutions, bioadhesive 
polymers, suspension, ointments and inserts possess several 
inherent disadvantages including blurred vision or difficulties in 
toleration or application into the eye. Hence, an “ideal” formulation 
would be easily dispensed, prolong residence time in the eye, and 
exhibit a controlled drug delivery over an extended period of time 
[2]. This goal might be achieved by using particulate carrier 
systems such as liposomes, microparticles and nanoparticles in 
ophthalmic drug delivery [3,4]. System of nanoparticles is one of 
ocular drug delivery systems which has been developed under the 
idea “prolonged residence time”. One of the rationalizations in 
supporting the therapeutic efficacy of nanoparticles is their  
 
 
 
 
mucoadhesive properties. The prolonged residence time can 
appreciably increase biological response and/or decrease the 
administration frequency [5,6]. 
In recent years, ophthalmic drug-loaded nanoparticles developed 
from poly-d,l-lactic acid, i.e., acyclovir [5], and bovine serum 
albumin, i.e., hydrocortisone [7] and pilocarpine [3,8] have been 
receiving appreciable interest since they are biodegradable and 
biocompatible. The pharmacokinetics of poly-d,l-lactic acid 
particles showed a controlled drug release, which could be elicited 
by mucoadhesion of the delivery system to the eye surface, thus 
allowing a long residence time and prolonged release compared 
to a drug suspension. The increase in drug bioavailability provided 
by PEG-coated poly-d,l-lactic acid particles could also be due to 
an enhancer effect [9]. Various in vivo studies in rabbits reported 
the prolonged effect of drug (pilocarpine, piroxicam) incorporated 
in albumin particles compared to commercial preparations or 
aqueous and viscous solutions [10]. Besides, it was reported that 
coadministration of pilocarpine-loaded albumin nanoparticles with 
various mucoadhesive polymers provided an effective means to 
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improve the miotic response as well as the intraocular pressure-
lowering response compared to the aqueous dispersion of the 
nanoparticles [3,8]. 
Acyclovir, an antiviral drug with a highly specific activity against 
herpes viruses, is widely used in the treatment of various ocular 
viral diseases. In particular, herpes simplex keratitis (in the most 
severe cases) is characterized by the spread of the virus into the 
deeper corneal layers, leading to damage of the stromal cells 
[11,12]. Therefore, treatment requires a suitable permeation of the 
antiviral drug through the epithelium in order to reduce the virus 
load. The topical application of acyclovir in ointments is limited by 
the low corneal penetration of the drug and by its poor water 
solubility (0.2 mg/ml). Many attempts have been made to improve 
the ocular bioavailability and the therapeutic efficacy of acyclovir 
by incorporating into colloidal systems such as liposomes [13,14] 
and nanoparticles [5]. In this study, acyclovir-loaded bovine serum 
albumin nanoparticles were developed after which their 
physicochemical properties and in vivo transcorneal 
permeabilities were assessed. 
Materials and Methods 
Materials 
Acyclovir micronized (ACV) was obtained from Zhejiang Wuyi 
Pharmaceutical Factory, China. Bovine serum albumin (fraction V) 
(BSA) was purchased from Merck, Darmstadt, Germany. Sodium 
phosphate monobasic dihydrate, sodium phosphate dibasic 
dodecahydrate, sodium chloride, and hydrochloric acid 37 % were 
from Labscan, Ireland. Atropine sulfate (T.P. Drug Laboratories, 
Thailand), xylazine hydrochloride (Troy Laboratories, Australia), 
isofurane USP (Halocarbon, USA), and zinc sulfate heptahydrate 
(BDH, England) 
Preparation of ACV-loaded BSA nanoparticles 
ACV-loaded BSA nanoparticles were prepared by the following 
desolvation technique under aseptic condition. BSA 500 mg 
together with 20 or 40 mg of ACV were dissolved in 10 ml 1:1 - 
ethanol : sterile water for injection (SWI), into which 15 ml of 
ethanol was submersibly pumped (Model 505S, Watson Marlow, 
USA) through a 1.0-mm spinal needle at 2 or 4 ml/min with 
continuous stirring at 500 rpm. The nanoparticles obtained were 
subject to hardening process at 60 °C for 2 hr under constant 
shaking in water bath, and finally purified by ultracentrifugation 
(Model Coulter LE-80K, Beckman, USA) at 32,000 rpm for 1 hr at 
4 °C and pellet washing with SWI. After 5 times washing, the 
nanoparticles were resuspended in 20 ml SWI and kept at 4 °C 
until use.  
Physicochemical characterization of ACV-loaded BSA 
nanoparticles 
 
Microscopic appearance and morphology 
Scanning electron microscopy (SEM) (Model JSM-5410LV, Jeol, 
Tokyo, Japan) was employed to examine the morphology and 
surface structure of ACV-loaded BSA nanoparticles. The samples 
were air-dried and covered with osmium tetroxide vapor 
approximately 1 hr for border contrast, which were subsequently 
dehydrated with ethanol in series and finally coated with a thin 
layer of gold. The magnification used was 35,000x. 
 
Particle size  
The particle sizes of ACV-loaded BSA nanoparticles were 
determined by photon correlation spectroscopy (PCS) using a 
submicron particle analyzer (Model N4MD, Coulter Corporate 
Communication, Hialeah, Florida, USA). The samples were 
measured at 25 ºC with scattering angle of 90º.  
 
Drug entrapment 
The amount of ACV entrapped in nanoparticles was determined 
by subtracting the initial amount of drug added into the system by 
the amount of free drug in the supernatant determined 
spectrophotometrically (DU 650i, Backman, USA) at 255 nm 
during the purification step. The drug entrapment efficiency of 
ACV-loaded nanoparticles was calculated as follows: 
 
% Entrapment efficiency   =    Amount of drug loaded   
                 x100  (1) 
  Initial amount of drug added into the system 
 
In addition, the drug loading capacity of ACV-loaded nanoparticles 
was calculated by the following equation: 
 
      % Loading capacity    = Amount of drug loaded    x 100 (2)
   Amount of carrier BSA 
 
Drug leakage 
At predetermined time intervals (0, 2, 4, and 8 weeks), 2 ml of 
ACV-loaded BSA nanoparticles dispersions was accurately 
pipetted into an ultrafiltration tube (30,000 MWCO) and then 
centrifuged (Universal 30 RF, Hettich, Germany) at 5,000 rpm for 
30 min. The amount of drug in filtrate was analyzed 
spectrophotometrically (DU 650i, Backman, USA) at 255 nm. The 
percentage of drug leakage from the nanoparticles was estimated 
according to the following equation: 
 
% Leakage= Amount of drug leaked   x 100  
           Amount of drug loaded   (3) 
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In vivo  transcorneal permeation study of ACV-loaded 
BSA nanoparticles 
Animal care 
Male New Zealand white rabbits (National Laboratory Animal 
Center, Mahidol University, Nakhon Pathom, Thailand) weighing 
from 2.0 - 3.0 kg, free of any sign of ocular inflammation or gross 
abnormality, were used. Animal procedures were ethically 
approved by the Institutional Animal Care and Use Committee, 
Faculty of Pharmacy, Mahidol University, Bangkok, Thailand. The 
approved number was No. 2/2550. In this study, the Laboratory 
Animal Center, National Institute of Health (NIH), Department of 
Medical Science, Ministry of Public Health, Thailand, was the 
animal house. The rabbits were in conventional animal room with 
strictly hygienic conditions. The temperature and humidity of the 
animal room were 23 - 27 °C and 60 - 90 % relative humidity, 
respectively.  Two rabbits were in the same stainless steel wire 
bottom cage with the size of about 17 x 14 x 25 in. The sterile 
shaved wood was bedded in the cage and changed every 2 days. 
Standard diet food and tap water were the routine feeding. The 
veterinarian routinely checked for health of rabbits every morning. 
Anterior chamber centesis was the technique to collect the 
aqueous humor for drug analysis. The rabbit was used only one 
time (not duplicate) in all studies. 
 
Irritation test 
According to Guideline for the Testing of Chemicals No. 405 
(Acute Eye Irritation/Corrosion) of OECD (Organization for 
Economic Co-operation and Development) [15], 100 µl of 
aqueous dispersion of ACV-loaded nanoparticles was applied in a 
single dose to one of the rabbit eyes. The untreated eye served 
as the control. The degree of eye irritation/corrosion was 
evaluated by scoring lesions of conjunctiva, cornea, and iris, at 
specific intervals. The experiment would be terminated at any time 
when the animal showed continuing signs of severe pain or 
distress. Observations were made at regular time intervals of 1, 
24, 48 and 72 hours, and scores were compiled for redness and 
swelling of the eye's conjunctiva, response of the iris to light, 
corneal opacity, and presence of discharge. These scores were 
compared with a classification table to determine which test 
materials were considered to be eye irritants. To determine 
reversibility of effects, the animals should be observed normally 
for 21 days post administration of the test substance. If 
reversibility was seen before 21 days, the experiment should be 
terminated at that time. 
 
Transcorneal permeation study 
ACV levels in aqueous humor were monitored at 30, 60, 90, and 
120 min after administrating 50 µl of aqueous dispersions of ACV-
loaded nanoparticles into the conjunctival sac of rabbit eyes. 
Fifteen minutes before paracentesis, the rabbits were 
preanesthetized by intramuscular injection with atropine sulfate at 
0.5 mg/kg dose and xylazine HCl at 5 mg/kg dose. Then five 
minutes before paracentesis, 4 % isofurane in oxygen was used 
as inhalation anesthetics for 2 min and maintained with 2 % of 
isofurane in oxygen during paracentesis. The paracentesis was 
closely supervised and checked by the veterinarian. Aqueous 
humor (150 µl) was withdrawn through the limbus by a syringe 
with 27G needle and stored at -20 °C. The samples were treated 
with a solution of 2 % w/v ZnSO4·7H2O at the ratio of 1:1, in order 
to deproteinize the aqueous humor, and then vortex-mixed and 
centrifuged (RC 5C Plus, Sorvall, USA) at 10,000 rpm for 1 hr at -
10 °C.  
The supernatant was analyzed for ACV by high performance 
liquid chromatography (HPLC) equipped with a high precision 
pump (LC-10AT VP, Shimadzu, Kyoto, Japan), UV-VIS detector 
(SPD-10A VP, Shimadzu, Kyoto, Japan) and system controller 
(SCL-10A VP, Shimadzu, Kyoto, Japan). A C18 reverse-phase 
column (Mightysil RP-18 GP Aqua 4.6 x 250 mm, Kanto chemical, 
Tokyo, Japan) was used at ambient temperature. The mobile 
phase was 0.1 % v/v glacial acetic acid solution at a flow rate of 
1.5 ml/min. The sample injection volume was 50 µl and the 
detection wavelength was 255 nm. ACV solutions in isotonic 
phosphate buffer pH 7.4 and aqueous humor ranging from 0.05 - 
0.25 mg/ml were used for the calibration curves with the r2 of 
0.9990 and 0.9790, respectively. The retention times of ACV in 
both media were about 14.7 min so that the runtime was 33 min. 
The accuracy of HPLC analytical method in terms of mean values 
(n = 3) of % recovery of ACV at 0.05, 0.15, and 0.25 mg/ml were 
92.97 + 1.83, 92.69 + 1.16, and 93.79 + 1.05 %, respectively. The 
precision of the assay procedure expressed as % CV’s (n = 3) at 
0.05, 0.15, and 0.25 mg/ml were 2.21, 1.90, and 1.13 % for within-
run, and 2.75, 2.02, and 1.78 % for between-run, respectively.  
Results and Discussion 
Preparation of ACV-loaded BSA nanoparticles 
The ACV-loaded BSA nanoparticles were prepared by desolvation 
technique. The basic principle of this technique is based on the 
desolvation and resolvation properties of proteins. Upon addition 
of desolvating agent such as ethanol, desolvation along with a 
progressive modification of the protein tertiary structure is 
induced, leading to the formation of protein aggregates when a 
certain degree of desolvation is obtained. The initially clear 
solution gradually turns opalescent as the protein becomes less 
soluble in water and tends to form nanometric aggregates of the 
desolvated protein, leading to a milky suspension. The drug 
molecules previously bound to the macromolecules by protein 
binding are entrapped within the polymer network prior to 
hardening by heat. The particle size of such ACV-loaded BSA 
nanoparticles was around 130 nm.  
 
Physicochemical characterization of ACV-loaded BSA 
nanoparticles 
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Microscopic appearance and morphology 
The scanning electron photomicrograph (SEM) of ACV-loaded 
BSA nanoparticles is shown in Figure 1, which appeared to be 
spherical in shape and nearly uniform in size. The size of BSA 
nanoparticles indicated by SEM was about 100 - 200 nm, which 
was subsequently confirmed by PCS. 
 
Particle size 
The mean sizes of ACV-loaded BSA nanoparticles produced from 
3 batches with different amounts of ACV added and solvent pump 
rates are shown in Table 1, which were in the range of 125-132 
nm. The reproducibility among 3 batches could be indicated. The 
nanosize range of BSA nanoparticles would ensure an intimately 
and effectively diffusive mixing between the bulk aqueous solution 
containing drug and the organic solvent jet stream containing 
polymer submergingly pumped into it. It can be seen that increase 
in quantity of ACV added into the formulation or slower solvent 
pump rate generally resulted in significantly larger nanoparticles 
(P < 0.05, ANOVA, LSD).  
 
Drug entrapment 
The values of entrapment efficiency and loading capacity of ACV-
loaded BSA nanoparticles shown in Table 1 were in the ranges of 
12.15 - 24.75 % and 0.86 - 1.21 %, respectively. The 
reproducibility among 3 batches could also be observed. The 
entrapment efficiency was significantly increased with the 
reducing amount of ACV added into the formulation or more rapid 
solvent pump rate (P < 0.05, ANOVA, LSD). This may be due to 
mixing behavior between the bulk aqueous solution containing 
drug and the organic solvent jet stream containing polymer 
submergingly pumped into it. It is stated that the volume of liquid 
entrained at the nominal boundary of the jet per unit time, causing 
the mixing in action, is proportional to the volume of liquid leaving 
jet nozzle per unit time [16]. Therefore, the mixing rate became 
increasing as the solvent pump rate was increased, which in turn 
resulted in ACV being adsorbed or embedded at a higher extent 
into the precipitated BSA nanoparticles. 
 
Drug leakage  
The % drug leakages from all formulations of ACV-loaded BSA 
nanoparticles upon storage at 4 ºC for 2, 4, and 8 weeks were 
found to be less than 0.9 %, which was the minimal detectable 
limit. Neither alteration in physical appearance nor aggregation 
was observed for all formulations of nanoparticles upon storage 
up to 2 months.  
 
In vivo  transcorneal permeation study of ACV-loaded 
BSA nanoparticles 
The ophthalmic colloidal formulations of ACV-loaded BSA 
nanoparticles chosen for further in vivo transcorneal permeation 
study in rabbits were those with 1.20 % loading capacities, the 
ACV concentration of which was 300 µg/ml. 
 
Irritation test 
Signs of irritation according to OECD guideline reported in terms 
of scores of irritation for ACV-loaded BSA nanoparticles are 
shown in Tables 2. It was found that all selected formulations of 
nanoparticles did not irritate the rabbit eyes so that further in vivo 
permeation study through rabbit cornea could be continued. 
 
Transcorneal permeation study 
The concentrations of ACV in rabbits’ aqueous humor at various 
time intervals after administrations of colloidal formulations of 
ACV-loaded BSA nanoparticles are shown in Figure 2. ACV-
loaded BSA nanoparticles could readily permeate through the 
cornea into aqueous humor, whose maximum concentration about 
18 ng/ml was reached within 30 min after administration. The drug 
concentrations could still be prolonged at this level up to 90 min, 
and then gradually declined till 120 min passed. The average 
values of in vivo “corneal permeability coefficient” (CPC) at 60 min 
after administrations of all ophthalmic formulations of ACV-loaded 
BSA nanoparticles studied was found to be 0.926 x 10-8 cm/sec.  
Conclusions 
ACV-loaded BSA nanoparticles could be reproducibly prepared by 
desolvation method. The nanoparticles obtained exhibited 
spherical shape and uniform nanosize about 100-200 nm with 
loading capacity of around 1-4 %. The in vivo transcorneal 
permeability of drug-loaded nanoparticles was shown to bring 
about adequate concentration in aqueous humor. 
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Figure 1. Scanning electron photomicrograph (SEM) of ACV-loaded BSA nanoparticles with 4 % drug loading. 
(35,000x magnification) 
 
 
 
 
Figure  2. Concentration profiles of ACV in rabbits’ aqueous humor after administrations of colloidal formulations 
of ACV-loaded BSA nanoparticles with ACV concentration of 300 µg/ml. Each point and bar represents mean and 
standard deviation from 3 determinations, respectively. 
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Table 1. Particle size, entrapment efficiency, and loading capacity of ACV-loaded BSA nanoparticles with different 
drug loadings and solvent pump rates 
 
ACV loading Solvent  
pump rate  
(ml/min) 
Mean ± SD a 
Particle size 
(nm) 
Entrapment 
efficiency (%) 
Loading 
capacity (%) 
4 % 2 132 ± 8 21.46 ± 0.07 0.86 ± 0.00 
4 126 ± 4 24.75 ± 0.11 0.99 ± 0.01 
8 % 2 125 ± 10 12.15 ± 0.17 0.97 ± 0.01 
4 131 ± 10 15.05 ± 0.10 1.20 ± 0.01 
   a Average from 3 determinations of 3 batches 
 
 
 
Table 2. Score of irritation test for ACV-loaded BSA nanoparticles 
 
Time 
interval (hr) 
Eye-side of administration Score 
Cornea Iris Conjunctivae Chemosis 
1 L = No drug administration 0 0 0 0 
R = BSA nanoparticles 0 0 0 0 
24 L = No drug administration 0 0 0 0 
R = BSA nanoparticles 0 0 0 0 
48 L = No drug administration 0 0 0 0 
R = BSA nanoparticles 0 0 0 0 
72 L = No drug administration 0 0 0 0 
R = BSA nanoparticles 0 0 0 0 
 
 
 
 
 
